Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT2C agonists for the treatment of metabolic disorders

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 1, 2011, Pages 34-37

  Tye, Heather ^a   Mueller, Stephan G ^b   Prestle, Juergen ^b   Scheuerer, Stefan ^b   Schindler, Marcus ^b   Nosse, Bernd ^b   Prevost, Natacha ^a   Brown, Christopher J ^a   Heifetz, Alexander ^a   Moeller, Clemens ^c   Pedret Dunn, Anna ^a   Whittaker, Mark ^a  

^a EVOTEC UK LTD   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c EVOTEC AG   (Germany)

Author keywords

5HT2C agonist; hERG inhbiiton; Metabolic disease

Indexed keywords

6,7,8,9 TETRAHYDRO 5H 1,4,7,10A TETRAAZA CYCLOHEPTA INDENE DERIVATIVE; LORCASERIN; POTASSIUM CHANNEL HERG; SEROTONIN 2C AGONIST; UNCLASSIFIED DRUG; VABICASERIN;

ARTICLE; CHO CELL; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; METABOLIC DISORDER; NONHUMAN; WEIGHT REDUCTION;

ANIMALS; AZA COMPOUNDS; AZEPINES; ETHER-A-GO-GO POTASSIUM CHANNELS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INDENES; MALE; METABOLIC DISEASES; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650514081     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.089     Document Type: Article

References (16)

1. D.A. Wacker, and K.J. Miller Curr. Opin. Drug Disc. Dev. 11 2008 438
2. J. Lee, M.E. Jung, and J. Lee Expert Opin. Ther. Patents 20 2010 1429
3. J.C.G. Halford, J.A. Harrold, E.J. Boyland, C.L. Lawton, and J.E. Blundell Drugs 67 2007 27
4. B.J. Nilsson J. Med. Chem. 49 2006 4023
5. B.M. Smith, W.J. Thomsen, and A.J. Grottick Expert Opin. Investig. Drugs 15 2006 257
6. D.E. Nichols Pharmacol. Ther. 101 2004 131
7. C.M. Villalon, and D. Centurion Naunyn-Schmeideberg's Arch. Pharmacol. 376 2007 45
8. B.L. Roth N. Eng. J. Med. 356 2007 6
9. B.M. Smith, J.M. Smith, J.H. Tsai, J.A. Schultz, C.A. Gilson, S.A. Estrada, R.R. Chen, D.M. Park, E.B. Prieto, C.S. Gallardo, D. Sengupta, P.I. Dosa, J.A. Covel, A. Ren, R.R. Webb, N.R.A. Beeley, M. Martin, M. Morgan, S. Espitia, H.R. Salanda, C. Bjenning, K.T. Whelan, A.J. Grottick, F. Menzaghi, and W.J. Thomsen J. Med. Chem. 51 2008 305
10. Ramamoorthy, P. S.; Beyer, C.; Brennan, J.; Dunlop, J.; Gove, S.; Grauer, S.; Harrison, B. L.; Lin, Q.; Malberg, J.; Marquis, K.; Mazandarani, H.; Piesla, M.; Pulicicchio, C.; Rosenzweig-Lipson, S.; Sabb, A.-M.; Schechter, L.; Stack, G.; Zhang, J. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States, March 26-30th, 2006, MEDI-021.
11. M. Lyles-Eggleston, R. Altundes, J. Xia, D.M.N. Sikazire, P. Fan, Q. Yang, S. Li, W. Zhang, W. Zhu, A.W. Schmidt, M. Vanese-Frawley, A. Shrikande, A. Villalobos, R.F. Borne, and S.Y. Ablordeppey J. Med. Chem. 47 2004 497
12. 50 value giving 50% of maximal activation.
13. A.M. Aranov Drug Discovery Today 10 2005 149
14. P.V. Fish, A.B. Brown, E. Evrard, and L.R. Roberts Bioorg. Med. Chem. Lett. 19 2009 1871
15. J.S. Stollack, and R.F. Furchgott J. Pharmacol. Exp. Ther. 224 1983 215
16. G.S. Baxter, O.E. Murphy, and T.P. Blackburn Br. J. Pharmacol. 112 1994 323